LICHTENSTEIN, HENRI,EDWARDS, NICHOLAS,RITCHIE, JAMES,PETERSEN, KAMILLE DUMONG,PLUMB, JANE
申请号：
CA2627923
公开号：
CA2627923C
申请日:
2006.11.10
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
The present invention relates generally to methods for treating cancer. In onerespect, the present invention relates to a method of treating a hematologicalcancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administeringto a patient in need thereof a therapeutically effective amount of a histonedeacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor asdescribed herein, for example, PXD-101. In another respect, the presentinvention relates to a method of treating cancer (e.g., solid tumour cancer,e.g., rectal cancer, colon cancer, ovarian cancer； hematological cancer, e.g.,multiple myeloma, leukemia, lymphoma) comprising administering to a patient inneed thereof, a first amount of a histone deacetylase (HDAC) inhibitor, forexample, a histone deacetylase inhibitor as described herein, for example, PXD-101 , and a second amount of an other chemotherapeutic agent, for example, another chemotherapeutic agent selected from: an antibody against VEGF,Avastin~, an antibody against CD20, rituximab, bortezomib, thalidomide,dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first andsecond amounts together comprise a therapeutically effective amount.
